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Abstract
Background: Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery
is not feasible, patients are treated with somatostatin analogs. However, the underlying mechanisms of action of this
treatment remain to be defined. The aim of the present study was to analyze the micro-RNA expression profile inter-
individually before and after the treatment with somatostatin analogs.
Material and methods: Tumor specimens of all included patients (n = 8) before and after the onset of a therapy with
somatostatin analogs were analyzed and a micro-RNA expression profile (754 micro-RNAs) of each probe was
generated. This analysis in an intra-individual setting was selected to avoid bias from inter-individual differences. The
micro-RNA expression profiles were validated by qPCR. Patients with any other systemic treatment were excluded from
the present study.
Results: Eight patients were included in the present study of which all had neuroendocrine tumors of the small intestine
with diffuse hepatic metastases. Grouped analyses revealed that 15 micro-RNAs were differentially expressed (3 up- and
12 downregulated) after the exposure to somatostatin analogs. Additionally, let-7c-5p and mir-3137 are concordantly
regulated in the inter-individually analysis.
Conclusions: This is the first study analyzing the individual micro-RNA expression profile before and after a therapy with
somatostatin analogs. Data from this study reveal that somatostatin analogs may in part exert their beneficial effects
through an alteration in the micro-RNA expression profile.
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Background
Neuroendocrine tumors of the small intestine (si-NETs)
account for 45% of gastroenteropancreatic neuroendo-
crine tumors (GEP-NETs) [1, 2]. Si-NETs are usually
small, but frequently lead to lymph node metastases
associated with a desmoplastic reaction of the mesentery
[3]. Moreover, although si-NETs are slow growing tu-
mors they frequently show liver metastases at the time
of initial diagnosis [4]. Thereby, even small tumors with
a favorable grading (commonly G1 or G2), can result in
a deteriorated prognosis due to distant metastases.
First line systemic treatment of well-differentiated
GEP-NETs consists of a biotherapy with somatostatin
analogs (SSAs) [5–7]. SSAs bind to somatostatin recep-
tors (SSTRs), which are abundantly expressed on GEP-
NETs [8]. Binding of SSAs leads to an activation of
SSTRs and an induction of complex intracellular signal-
ing pathways with subsequent alterations in cell function
(exocrine ability, growth, viability) [9]. The anti-
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: florian.boesch@med.uni-muenchen.de
1Department of General, Visceral, and Transplant Surgery,
Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377 Munich,
Germany
6Interdisciplinary Center of Neuroendocrine Tumors of the
GastroEnteroPancreatic System, Ludwig-Maximilians-University Munich,
Munich, Germany
Full list of author information is available at the end of the article
Bösch et al. BMC Cancer          (2019) 19:575 
https://doi.org/10.1186/s12885-019-5794-y
proliferative properties of SSAs have been validated in
two multicenter prospective studies [10, 11].
Micro-RNAs (miRNAs), small non-coding RNA mole-
cules (18–25 nucleotides), have been shown to modulate
cell proliferation, differentiation, and apoptosis. The
modulation takes place at post-transcriptional levels and
their specific role in cancer can be either as an oncogene
or as a tumor suppressor [12–14]. MiRNAs can be de-
tected by a fully automated, high throughput procedure.
Thereby, these small molecules might gain increased
interest as diagnostic and/or prognostic markers. Indeed,
previous studies revealed that miRNAs may act as prog-
nostic biomarkers for different cancer types [15–17] or
even as targets for tumor directed therapy [18]. Further-
more, the various entities of GEP-NETs (pancreas, small
intestine, etc.) have each a distinct miRNA expression
profile [19–21] and miRNAs might act as biomarkers
[22, 23].
So far the exact underlying mechanisms of action of
the SSA therapy need to be defined. We therefore ad-
dressed the present study to analyze individual miRNA
expression profiles before and after SSA treatment.
Material and methods
Study cohort
Data of patients diagnosed with a GEP-NET who under-
went surgery at our Department between 01/2000 and 12/
2017 were collected in a prospective led database. For in-
clusion in the present study, a tumor specimen from every
single patient before the onset of the biotherapy (group A)
and a tumor sample after the onset of the biotherapy
(group B) were necessary. Patients with any other systemic
anti-tumor therapy were excluded. Eight patients met all
criteria and were included in the present study (Table 1).
Patients were selected from a surgical collective published
earlier [3, 24] and were analyzed in this work in respect to
the miRNA expression profile [25].
All patients underwent complete primary tumor resec-
tion at the Department of General, Visceral and Trans-
plant Surgery at the Ludwig-Maximilians-University of
Munich, Germany. Every specimen underwent routine
processing and examination at the Institute of Pathology
at the Ludwig-Maximilians-University of Munich,
Germany.
RNA and miRNA isolation
Freshly sliced formalin-fixed paraffin-embedded (FFPE)
tumor sections were used for the experiments which
were done under sterile, RNAse, and DNAse free condi-
tions. RNA extraction was done by microscope assisted
microdissection supervised by an experienced patholo-
gist (T.K.) with special expertise in GEP-NET pathology.
Before microdissection the tumor area of each specimen
was precisely marked on a hematoxylin and eosin
stained serial slide to exclude necrotic area or adjacent
tissue. The dissected tumor tissue was transferred into
1.5 ml tubes and further purified by using the miRNeasy
FFPE Kit (Qiagen, Hilden) according manufacturer’s in-
structions. NanoDrop 2000 (Thermo Fisher Scientific,
Waltham, MA) spectrophotometer was used to quantify
the amount and the quality of nucleotide acids and only
samples, which passed the quality control (A260/280 >
2.0, clear single RNA peak) were further processed.
Analysis of differentially expressed miRNAs
Pre-amplification of cDNA was performed with miRNA
specific primers as provided with the Megaplex™ Primer
Pools, Human Pools Set v3.0 (Applied Biosystems).
Fluorescently-labeled miRNA were prepared according to
Agilent protocol “miRNA Complete Labeling and Hyb
Kit”. 100 ng labeled miRNA sample were hybridized for at
least 20 h at 55 °C on Agilent human miRNA Microarray
Release 21.0, 8x60k. The cDNAs were then diluted and
loaded onto a TaqMan® Array Human MicroRNA A+ B
Cards Set (Applied Biosystems) and qRT-PCR run per-
formed. RNU6-2_11 and RNU6_11 served as housekeep-
ing genes on all Taqman Low Density Array (TLDA)
cards run. Fold changes in expression were calculated for
all miRNAs by dividing mean values from group B with
group A. Gene Expression Microarrays were scanned
using the Agilent Scanner G2505C. The scanned images
Table 1 Patients included in the present analysis (SSA: somatostatin analog)
Patient Source before SSA Source after SSA Treatment period (months)
1 Liver metastasis Primary tumor 3
2 Liver metastasis Primary tumor 13
3 Liver metastasis Primary tumor 5
4 Primary tumor Liver metastasis 2
5 Liver metastasis Primary tumor 1
6 Liver metastasis Primary tumor 1
7 Liver metastasis Primary tumor 1
8 Liver metastasis Primary tumor 1
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were analyzed with Feature Extraction Software (Agilent
technologies) using default settings.
Reverse transcription and qRT-PCR
miRNA was reverse-transcribed using the miScript II RT
Kit (Qiagen) according to manufacturer’s protocol. The
cDNA was then diluted with RNase-free water and fro-
zen until qPCR. cDNA was thawed and qPCR was per-
formed using the miScript SYBR Green PCR Kit
(Qiagen) and the 10x miScript Primer Assays (Qiagen)
for the miRNAs of interest according to manufacturer’s
protocol as described elsewhere [26]. The runs were per-
formed on a StepOne Plus real-time PCR system (Ap-
plied Biosystems). RNU6-2_11 served as housekeeping
gene. Fold changes in expression were calculated for all
miRNAs using the delta Ct (dCt) method (dCT (target
sample) = CT (target gene) – CT (housekeeping gene)).
Statistical analyses
All statistical analyses were performed by using Prism
6.0 for Mac (GraphPad Software, Inc., La Jolla, CA).
Results
Study cohort
In total, the database consists of 517 patients who
underwent surgery for a GEP-NET. Out of these patients
eight patients eligible for the study were identified. Every
analyzed patient had a si-NET, lymph node and liver
metastases. Mean age of the patients was 60.1 years
(47.3–72.4 years) and five were female. Patient character-
istics are displayed in Table 2.
MiRNA expression profile
To attain an individual miRNA expression profile of
every patient as a baseline, in the first step, a tumor
sample of every patient was analyzed before the onset of
a biotherapy with SSAs. In the second step, the effect of
SSAs was analyzed. Therefore, tumor specimens of the
same patients were analyzed again after the onset of the
biotherapy. For every analysis of a specimen a single
array card was used and 758 miRNAs (754 target miR-
NAs and 4 control RNAs) were quantified by TLDA.
Paired specimens (i.e. 1A vs. 1B; 2A vs. 2B) were ana-
lyzed to clearly identify effects of a SSA treatment on
the miRNA expression profile. By the use of this experi-
mental design inter-individual alterations in the miRNA
profile were ruled out. The analysis revealed that
biotherapy with SSAs lead to an alteration in the miRNA
expression profile (Fig. 1).
Validation of miRNA by RT-PCR
Thirty-six miRNAs (20 most downregulated and 16
most upregulated, respectively), which were highly dif-
ferentially expressed in TLDA cards, were identified by
grouping (1A-8A vs. 1B-8B) the results. To validate the
expression of these 36 miRNAs, qPCR of the same eight
samples before and after treatment were analyzed. Al-
though validation by qPCR was conducted for every sin-
gle specimen the results were grouped thereafter.
The validation of the 36 miRNAs confirmed that 15 miR-
NAs are expressed differentially. SSA treatment induced an
upregulation of three miRNAs (let-7c-5p, mir-24-3p, and
mir-215-5p) and a downregulation of twelve miRNAs (mir-
10a-3p, mir-185-3p, mir-339-5p, mir-371a-5p, mir-4436b-
5p, mir-4653-3p, mir-4793-3p, mir-619-5p, mir-1226-3p,
mir-3137, mir-4455, and mir-4656) (Table 3).
MiRNA expression in single patients before and after SSA
therapy
As mentioned above, the grouped miRNA expression
profile is different before and after SSA therapy. In the
next step, the differences in the miRNA expression pro-
file for each patient had to be elucidated. Therefore, the
individual qPCR values were compared.
This analysis revealed that let-7c-5p was concordantly
upregulated in every patient after SSA therapy (Fig. 2a).
Additionally, mir-3137 was concordantly downregulated
in every patient after SSA therapy (Fig. 2b). The grouped
Table 2 Patient characteristics of the eight analyzed patients (T: primary tumor stage; N1: lymph node metastases; M1: distant metastases;
L0/1/x: lymphatic vessel infiltration (no/yes/no information); V0/1/x: Angioinvasion (no/yes/no information); Pn0/1/x: Perineural infiltration
(no/yes/no information; unk.: unknown))
Patient Age (years) Primary tumor Tumor staging Size (cm) Grading Alive
1 66.8 small intestine T3, N1 (50/82), M1, L1, V0, Pn1 1.3 2 yes
2 59.5 small intestine T2, N1 (4/31), M1, L0, V0, Pn0 1.5 2 yes
3 57.0 small intestine T4, N1 (8/28), M1, L1, V0, Pn1 1.6 2 yes
4 62.5 small intestine T3, N1 (3/19), M1, L1, V1, Pn1 1.8 1 yes
5 47.3 small intestine T3, N1 (5/24), M1, L1, V0, Pn0 1.5 2 yes
6 49.4 small intestine T3, N1 (3/14), M1, L1, V0, Pn1 2.1 1 yes
7 65.9 small intestine T4, N1 (3/16), M1, Lx, Vx, Pnx unk. 2 no
8 72.4 small intestine T3, N1 (5/50), M1, L1, V0, Pn0 0.8 1 yes
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analyses revealed that let-7c-5p was upregulated 9.53
times and mir-3137 was downregulated 0.44 times.
Discussion
GEP-NETs demand more attention since the incidence
is increasing [27]. The clinical importance of this entity
is further underlined by the fact that even small tumors
may lead to distant metastases [24]. The most validated
prognostic marker is tumor grading, but si-NETs are
commonly well-differentiated (G1 or G2). Thus, novel
diagnostic biomarkers are needed. Moreover, there are
no prognostic markers or tools to monitor therapeutic
effects. Previous studies revealed an important role of
miRNAs in various tumors that these can either act as
an oncogene or a tumor suppressor. MiRNAs show a
high stability in vitro and persistence in vivo. Therefore,
analyzing miRNA signatures is even in FFPE tissue
highly sensitive [28]. Furthermore, it was shown that the
blockade or the replacement of a distinct miRNA can be
used as a therapeutic approach [18]. Moreover, miRNAs
seem to play a role in NETs and can be used as a bio-
marker, as demonstrated recently [22, 29, 30].
Fig. 1 The heat map of the micro-RNA profiles analyzed
Table 3 Differentially expressed micro-RNAs, which were validated
by PCR for the entire collective
microRNA Fold change
let-7c-5p 9.53
mir-10a-3p 0.88
mir-24-3p 4.76
mir-185-3p 0.7
mir-215-5p 12.64
mir-339-5p 0.75
mir-371a-5p 0.36
mir-619-5p 0.75
mir-1226-3p 0.56
mir-3137 0.44
mir-4436b-5p 0.97
mir-4455 0.52
mir-4653-3p 0.7
mir-4656 0.73
mir-4793-3p 0.55
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This is the first study analyzing the individual effect of
a biotherapy with SSAs on the miRNA expression profile
in si-NETs. The questioning of the present study cares
aim to exclude inter-individual differences, subsequently
only patients with tumor samples available before and
after the onset of biotherapy were included. The gener-
ation of controls would lead to inter-individual differ-
ences and further hamper the interpretation of the
results. In addition, miRNA expression profile alterations
might be time dependent. But, the effects of time on the
miRNA signature have not been investigated so far. In
this respect, recent publications used normal tissue of
the small intestine or the liver [30–32] as controls. But,
this approach of generating a control collective was not
appropriate for this analysis. Additionally, patients re-
ceiving any other systemic therapy were excluded in the
present study. Thus, a very uniform study collective was
generated and subsequently analyzed. It should be noted
that the results of the present study analyzing si-NETs
cannot be automatically extrapolated for NETs outside
the small intestine. As a result of this approach the dir-
ect effect of a SSA therapy could be evaluated on the
post-transcriptional level. MiRNAs will gain further at-
tention since they can be detected fully automated in a
high throughput technique. One would speculate that
the protein expression might be different as a conse-
quence of biotherapy. However, these effects have to be
validated in a first step with in vitro trials since miRNAs
have an abundance of target genes. Furthermore, the pa-
tient collective might be too small to demonstrate clin-
ical effects. Nonetheless, the present study provides
miRNA profiles to stimulate further research and evalu-
ate the clinical relevance in a larger patient collective in
a prospective multicenter study. Additionally, it is pos-
sible to determine miRNA profiles in serum samples,
making liquid biopsies possible [29, 33, 34]. It was dem-
onstrated in colorectal cancer that a distinct expression
profile is associated with deteriorated survival rates [15].
In particular for example, mir-215 seems to be a sup-
pressor of tumor progression in colorectal cancer [35,
36]. Additionally, it was seen in ovarian cancer, non-
small cell lung cancer (NSCLC), and breast cancer that
specific miRNAs lead to a shortened tumor-free survival
[37–39]. In this respect, mir-215 might be a key player.
In vitro studies demonstrated that the upregulation of
mir-215 leads to apoptosis in colorectal and NSCLC
cancer cells [36, 38]. In line with these findings, the
present miRNA profiling revealed that after SSA treat-
ment mir-215 was highly upregulated indicating a poten-
tial antitumoral mechanism of action of SSA-therapy.
The results of the present study suggest that miRNAs
represent a promising tool to monitor antitumor ther-
apy. Moreover, future multicenter prospective studies
should aim to clarify if biotherapy induces long-term al-
terations in miRNA expression profiles.
There are only few studies highlighting the effect of
miRNAs and neuroendocrine tumors [19–21]. In this re-
spect, the results of this analysis suggest that biotherapy
directly influences the miRNA expression profile. The
differences seen were intra-individual changes most
probably induced by somatostatin therapy. There is a
growing body of evidence, which suggests that miRNAs
might serve as biomarkers in the near future. Panarelli
et al. recently published their work on miRNA signa-
tures and add further evidence for the importance of
miRNAs. They have demonstrated that GEP-NETs can
be classified and graded with the use of miRNAs. The
authors could develop a classification system with a high
accuracy based on miRNA expression profiles [40].
However, most of the miRNAs detected by Panarelli et
al. did not play a role in the current analysis or in other
studies [19, 29, 41]. It was shown that the miRNA ex-
pression profile is dependent on the tumor stage [19].
The inclusion criteria (two tumor samples of the same
patient prior to and after the initiation of SSA treatment
and no further systemic treatment) consecutively led to
a numerically small patient collective. From a clinical
point of view assessment of tumor tissue of the primary
is impossible in most patients preoperatively since the
majority of small intestine NETs cannot be reached
Fig. 2 a Expression levels of the uniformly regulated micro-RNAs. let-7c-5p could be analyzed in patients 2–8 and was concordantly regulated. b
mir-3137 could be analyzed in patients 2 and 4–8 and was concordantly regulated
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endoscopically. Commonly these tumors are incidentally
diagnosed by routine sonography of the liver. Thus, the
initial tumor specimens are liver biopsies, subsequently
leading to the initiation of SSA treatment. Therefore we
had to analyze primary tumors as well as liver
metastases.
Furthermore, previous studies have demonstrated that
the miRNA expression profile differs between the primary
tumor and (lymph node) metastases [19, 32], but the exact
pathogenetic role of miRNAs remains ill-defined [22]. Pre-
vious studies have compared the primary tumor with adja-
cent normal tissue, liver metastases with normal liver or
the primary tumor with liver metastases. The results of
these heterogeneous analyses are inconsistent and concord-
ant dysregulated miRNA signatures have not been pub-
lished. Miller et al. demonstrated recently that the primary
tumor and liver metastases even share 29 concordantly up-
regulated miRNAs [32]. Moreover, Heverhagen et al. dem-
onstrated that liver metastases were nearly similar to the
primary tumor [30]. The already characterized and pub-
lished miRNAs (except let-7c), however, did not play a role
in the present study. Regarding let-7c, our results are sup-
ported by Døssing et al. who recently have shown that SSA
leads to an upregulation of let-7 family members [42],
which inhibits the growth of carcinoid cell lines [31].
Therefore, the alterations seen in the present study may in
part be induced by SSA treatment and adds further infor-
mation in assessing the role of miRNAs in neuroendocrine
tumors. Within the present study it was demonstrated for
the first time that a biotherapy with SSAs leads to an alter-
ation of the miRNA profile in tumor specimens of si-NETs.
Three miRNAs were upregulated and 12 miRNAs were
downregulated due to SSA treatment. Out of this grouped
analysis two miRNAs (let-7c-5p and mir-3137) were found
to be regulated concordantly in every single patient. Thus,
it is suggested that the beneficial effects of somatostatin an-
alogs are in part be mediated through these miRNAs. In
silico analyses have revealed that the miRNAs, which are
expressed differentially, have anti-tumor properties. Espe-
cially, the downregulation of let-7c-5p was associated with
a worse outcome in pancreatic adenocarcinoma as well as
in breast and lung cancer [43–45]. However, there are no
reports available about the specific properties of let-7c-5p
in GEP-NETs. Therefore, further prospective studies are
demanded to elucidate the effect of let-7c-5p in GEP-NETs.
The alterations between the primary tumor and its me-
tastases are of great interest and further studies are
needed. However, analyzing the differences of primary tu-
mors, its liver metastases and further distant metastases
was beyond the scope of this manuscript. Further support
for the relevance of the presented data, despite expected
tumor heterogeneity, comes from the clinical observation
that response to SSA treatment is homogenous between
metastases and primary tumors. A solitary progression of
distant metastases is only seen after years of treatment.
Therefore, the results of this analysis with a homogenous
patient collective consisting only of patients with si-NETs
indicate that SSA treatment directly leads to alterations in
the miRNA signature.
SSTR type-2 (SSTR2) is abundantly expressed on the
surface of well-differentiated GEP-NETs [8, 42]. In this re-
spect, in silico target gene analyses revealed that mir-185-
3p directly interacts with SSTR2. Thus, the anti-tumor
effect of SSAs might be in part mediated by downregula-
tion of mir-185-3p. In this respect, it was shown recently
that the downregulation of mir-185-3p is beneficial in
nasopharyngeal carcinoma cell lines [46]. However, there
is no distinct literature about specific effects of mir-3137,
but target analyses showed that mir-3137 also interacts
with SSTR2. Therefore, downregulation of mir-3137
might be a direct effect of the treatment with SSAs or the
antitumor properties of SSAs are mediated at least in part
via mir-3137 downregulation. The downregulation of mir-
185-3p and mir-3137 and the upregulation of let-7c-5p or
mir-215-5p may represent potential targets in the future.
Thus, large prospective multicenter studies are necessary
to address the future role of miRNAs in GEP-NETs.
Despite the promising results of the present study, there
are several limitations as well. This is a retrospective ana-
lysis, however, based on a prospective led database. Further-
more, the source of the tumor samples is diverging. Due to
the inclusion criteria (two tumor samples of each patient,
no other systemic treatment) the patient cohort is numeric-
ally small and primary tumors as well as liver metastases
had to be analyzed. In this respect, previous studies have
demonstrated that the miRNA expression profile differs be-
tween the primary tumor and (lymph node) metastases [19,
32]. However, these miRNA signatures are not concordant
and the previously published miRNAs did not play a role in
the present manuscript, except of one miRNA. The SSA-
treatment period is slightly different, which might influence
miRNA expression profiles. However, the effect of any
other systemic therapy could be ruled out since these pa-
tients were not included. In addition, from in vitro studies
it is known that SSA inhibits cell growth within a short
period of time and pharmacokinetic studies with humans
revealed similar results [47, 48]. A control collective would
be desirable. But, due to the rare incidence and the ques-
tioning a control collective was not provided.
Conclusions
In conclusion, we demonstrat for the first time that the
biotherapy with SSAs leads to an alteration of the
miRNA expression profile. Especially, let-7c-5p and mir-
3137 seem to be of great interest as these miRNAs were
regulated uniformly in every patient. In this respect, fu-
ture studies with larger cohorts are necessary to confirm
the effects of miRNAs.
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